Ulcerative colitis (UC) is an autoimmune inflammatory chronic disease, which compromises
the colonic mucosa continuously, affecting the rectum with a variable proximal extension
to the cecum, in a relapsing and remitting way. The higher incidences and prevalence are
described in Europe and North America,...
Biological therapies have been essential for the management of inflammatory bowel disease; however, their
high cost results in many patients being unable to access them. With time, commercial patents of many
“original” biologics are reaching or almost in the point of reaching the expiration date of t...
ABSTRACT BACKGROUND: Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases. In such pathologies, there is an increased production of alpha tumor necrosis factor (TNF-α). Patients, in whom the conventional immunosuppressant treatment fails, require the use of immunobiologica...
Estudios de Cohortes,
Colitis Ulcerosa/sangre,
Colitis Ulcerosa/tratamiento farmacológico,
Enfermedad de Crohn/sangre,
Enfermedad de Crohn/tratamiento farmacológico,
Estudios Transversales,
Fármacos Gastrointestinales/sangre,
Fármacos Gastrointestinales/uso terapéutico,
Infliximab/sangre,
Infliximab/uso terapéutico,
Persona de Mediana Edad,
Estudios Retrospectivos,
Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
Zacharias, Patrícia;
Damião, Aderson Omar Mourão Cintra;
Moraes, Antonio Carlos;
Teixeira, Fábio Vieira;
Ludvig, Juliano Coelho;
Nones, Rodrigo Bremer;
Saad-Hossne, Rogerio;
Sassaki, Ligia Yukie;
Silva, Rosemary Pereira Lino da;
Facchin, Luiza;
Olandoski, Marcia;
Kotze, Paulo Gustavo.
ABSTRACT BACKGROUND: Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. OBJ...
Primary colorectal lymphoma is a rare form of presentation of gastrointestinal tract lymphomas. Inflammatory bowel disease and its treatment are risk factors for its development. We report a 47-year-old male patient with Ulcerative Colitis of two years of evolution, treated initially with azathioprine an...
Colitis Ulcerosa/tratamiento farmacológico,
Inmunosupresores/efectos adversos,
Linfoma de Células B Grandes Difuso/etiología,
Linfoma de Células B Grandes Difuso/patología,
Neoplasias del Recto/etiología,
Neoplasias del Recto/patología,
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico,
Azatioprina/efectos adversos,
Biopsia,
Ciclofosfamida/administración & dosificación,
Doxorrubicina/administración & dosificación,
Fármacos Gastrointestinales/efectos adversos,
Infliximab/efectos adversos,
Linfoma de Células B Grandes Difuso/diagnóstico por imagen,
Tomografía Computarizada por Tomografía de Emisión de Positrones,
Prednisona/administración & dosificación,
Neoplasias del Recto/diagnóstico por imagen,
Rituximab/administración & dosificación,
Vincristina/administración & dosificación
De La Fuente, Marjorie;
Chahuán, Isidora;
Gutiérrez, RocÍo;
Díaz-Jiménez, David;
Olivares, Mauricio;
Vidal, Roberto;
Simian, Daniela;
Figueroa, Carolina;
Quera, Rodrigo;
Hermoso, Marcela A.
Background: Different strains of invasive Escherichia coli (E. coli), isolated from intestinal mucosa of patients, are related to the pathogenesis of inflammatory bowel diseases (IBD). Aim: To evaluate an association between intracellular E. coli and IBD; its clinical characteristics and use of steroids...
Colitis Ulcerosa/microbiología,
Escherichia coli/aislamiento & purificación,
Enfermedad de Crohn/microbiología,
Mucosa Intestinal/microbiología,
Corticoesteroides/uso terapéutico,
Antiinflamatorios/uso terapéutico,
Estudios de Casos y Controles,
Colitis Ulcerosa/tratamiento farmacológico,
Recuento de Colonia Microbiana,
Enfermedad de Crohn/tratamiento farmacológico,
Estudios Prospectivos,
Valores de Referencia,
Estadísticas no Paramétricas
Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that sup...
Colitis Ulcerosa/tratamiento farmacológico,
Fármacos Gastrointestinales/uso terapéutico,
Infliximab/uso terapéutico,
Enfermedad Aguda,
Biopsia,
Colitis Ulcerosa/diagnóstico por imagen,
Colitis Ulcerosa/patología,
Colonoscopía,
Heces,
Complejo de Antígeno L1 de Leucocito/análisis,
Resultado del Tratamiento
ABSTRACT BACKGROUND There is evidence that shows that calcineurin inhibitors may be useful for the treatment of severe ulcerative colitis. However, evidence regarding the efficacy of tacrolimus for remission induction in this setting is scarce. OBJECTIVE To develop a systematic review on the existing...
INTRODUCCIÓN: Antecedentes: El presente dictamen expone la evaluación de tecnologia de la eficacia y seguridad de golimumab en pacientes con colitis ulcerativa moderada o severa, refractaria al tratamiento convencional y biológico con infliximab. Aspectos Generales: La colitis ulcerativa (CU) es la co...
